HMG-CoA reductase inhibitor pravastatin ameriolates left ventricular dysfunction through inhibition of oxidative stress and inflammation in a canine model of tachycardia-induced heart failure

被引：0
|
作者：
Nakamura, R [1 ]
Egashira, K [1 ]
机构：
[1] Kyushu Univ, Grad Sch Med Sci, Fukuoka 812, Japan
来源：
CIRCULATION | 2001年 / 104卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1186
引用
收藏
页码：247 / 247
页数：1
相关论文
共 25 条
  • [21] ADD-ON THERAPY WITH HMG-COA-REDUCTASE INHIBITORS MAY LOWER THE RISK FOR INCIDENT LEFT VENTRICULAR DYSFUNCTION plus /- HEART FAILURE IN EPIRUBICIN RECIPIENTS WITH GASTRIC CANCER
    Tase, Adrian
    Titus, Ovidiu T.
    Tase, Anca
    Savoiu, Gheorghe
    Iorga-Siman, Ion
    Mihaila, Marius
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A932 - A932
  • [22] Huoxin pill protects verapamil-induced zebrafish heart failure through inhibition of oxidative stress-triggered inflammation and apoptosis
    Li, Xianmei
    Zeng, Laifeng
    Qu, Zhixin
    Zhang, Fenghua
    HELIYON, 2024, 10 (01)
  • [23] Co-administration of Coenzyme Q10 and HMG-CoA Reductase Inhibitor Attenuates Oxidative Stress, TGF-β, TNF-α, Nitrite Content and MPO Levels against Experimentally-induced Diabetic Nephropathy in Rats
    Maheshwari, Rajesh A.
    Sen, Ashim Kumar
    Balaraman, Ramachandran
    Shah, Nirmal, V
    Shah, Umang H.
    Solanki, Nilay
    Sen, Dhanya B.
    INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH, 2022, 56 (04) : 1091 - 1098
  • [24] Graft protective effects and donor-specific antibody suppression by CD4+CD25+Foxp3+ regulatory T cell induced by HMG-CoA reductase inhibitor rosuvastatin in a murine heart transplant model
    Iguchi, Kazuhito
    Yamamoto, Yasuto
    Uchiyama, Masateru
    Masaoka, Hisanori
    Nakamura, Masahiro
    Shizuka, Hiroyuki
    Imazuru, Tomohiro
    Shimokawa, Tomoki
    JOURNAL OF CARDIOTHORACIC SURGERY, 2024, 19 (01)
  • [25] Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level
    Bleske, BE
    Nicklas, JM
    Bard, RL
    Brook, RD
    Gurbel, PA
    Bliden, KP
    Rajagopalan, S
    Pitt, B
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (02) : 338 - 341
123